2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/07/18Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million, before deducting the underwriting discounts and commissions and other estimated off... 
Printer Friendly Version
12/06/18Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agreement to sell $150.0 million in shares of its common stock in a registered underwritten public offering.  In addition, GBT has granted the underwriter a 30-day option to purchase up to $22.5 milli... 
Printer Friendly Version
12/04/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 30, 2018, the compensation committee of the Company’s board of directors granted six new employees options to purchase an aggregate of 29,250 shares of the Company’s common stock with a per share exercise price of $31.54, the closing trading price on the grant date, and restricted stock units for an aggregate of 19,350 shares of the... 
Printer Friendly Version
12/03/18GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
Interim Analysis of Data from 1500 mg Cohort of HOPE-KIDS 1 Study Consistent with Phase 3 HOPE- Results in Demonstrating Improvement in Hemoglobin and Clinical Measures of Hemolysis and Favorable Safety in Pediatric Patients Company to Host Investor Webcast Today, Monday, December 3, at 12:00 p.m. PT/3:00 p.m. ET, to Discuss Data SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) today announced updated efficacy and safety res... 
Printer Friendly Version
12/03/18GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
Pre-NDA Meeting to be Requested for First Quarter of 2019 Company to Host Conference Call and Webcast Today, Monday, December 3, at 5:30 a.m. PT/8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) today announced that the U.S. Food and Drug Administration (FDA) has informed GBT through discussions and written correspondence that the agency agrees with the Company’s proposal relating to use of an accelerated appr... 
Printer Friendly Version
12/02/18GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the company will host a conference call to provide a regulatory update for voxelotor tomorrow, Monday, December 3, 2018, at 8:30 a.m. ET. To participate in the conference call, please dial (844) 471-0808 (domestic) or (480) 696-7309 (international) and refer to conference ID 9327146. Live audio of the conference call will be simultaneously web... 
Printer Friendly Version
11/06/18GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the third quarter ended September 30, 2018. “Voxelotor has the potential to be a transformative treatment for the sickle cell community. We remain in active discussions with the U.S. Food and Drug Administration regarding the potential for accelerated approval of voxelotor. We continue to believe that voxelotor meets th... 
Printer Friendly Version
11/06/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 1, 2018, the compensation committee of the Company’s board of directors granted seven new employees options to purchase an aggregate of 23,750 shares of the Company’s common stock with a per share exercise price of $39.41, the closing trading price on the grant date, and restricted stock units for an aggregate of 15,700 shares of th... 
Printer Friendly Version
11/01/18GBT Announces Upcoming Data Presentations at 60th American Society of Hematology (ASH) Annual Meeting & Exposition
Company to Present Three Oral Presentations, Including Results Beyond 12 Weeks from Part A of the HOPE Study Company to Host Investor Webcast on Monday, December 3 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD) development programs, including voxelotor, have been accepted for oral and poster presentation during the 60th American Society of Hematolog... 
Printer Friendly Version
10/04/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on October 1, 2018, the compensation committee of the Company’s board of directors granted 10 new employees options to purchase an aggregate of 63,250 shares of the Company’s common stock with a per share exercise price of $36.90, the closing trading price on the grant date, and restricted stock units for an aggregate of 42,800 shares of the Company’s common ... 
Printer Friendly Version
10/04/18GBT Announces Upcoming Presentations at National Sickle Cell Disease Association of America (SCDAA) Convention
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that three abstracts related to its sickle cell disease (SCD) development programs, including voxelotor, have been accepted for oral presentation during the 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention in Baltimore, MD, taking place October 10-13, 2018. Additionally, GBT will host a lunch symposium at the conference titled, “He... 
Printer Friendly Version
09/26/18GBT Announces Participation at the 2018 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Cantor Global Healthcare Conference in New York City on Tuesday, October 2 at 1:05 p.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver... 
Printer Friendly Version
09/07/18GBT Announces Participation at the 2018 Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Morgan Stanley Global Healthcare Conference in New York City on Friday, September 14 at 10:30 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, develop ... 
Printer Friendly Version
09/06/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on September 4, 2018, the compensation committee of the Company’s board of directors granted five new employees options to purchase an aggregate of 71,000 shares of the Company’s common stock with a per share exercise price of $49.50, the closing trading price on the grant date, and restricted stock units for an aggregate of 48,150 shares of the Company’s co... 
Printer Friendly Version
09/06/18GBT Brings Together Sickle Cell Disease Influencers at 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Healthcare Providers, Patient Advocates and Policy Makers Will Discuss Issues Impacting SCD Community During National SCD Awareness Month Livestream of Conference Will Be Available through Collaboration with Sickle Cell Warriors SOUTH SAN FRANCISCO, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will host the 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Thursday, September 13, 2018, at the Park Central ... 
Printer Friendly Version
08/23/18GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche Ltd. for the development and commercialization of inclacumab, a novel fully human monoclonal antibody against P-selectin. GBT plans to develop inclacumab as a treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD).  Under the terms of the a... 
Printer Friendly Version
08/21/18GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs. At GBT, Ms. Wagner will create and lead the Company’s government affairs and public policy function, initially focused on concerns related to the sickle cell di... 
Printer Friendly Version
08/07/18GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 14 at 10:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deli... 
Printer Friendly Version
08/03/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on August 1, 2018, the compensation committee of the Company’s board of directors granted two new employees options to purchase an aggregate of 2,500 shares of the Company’s common stock with a per share exercise price of $43.15, the closing trading price on the grant date, and restricted stock units for an aggregate of 1,650 shares of the Company’s common st... 
Printer Friendly Version
08/02/18GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the second quarter ended June 30, 2018. "We continue to advance our voxelotor clinical development program with the goal of bringing this potentially transformative treatment to the sickle cell disease, or SCD, community as soon as possible,” said Ted W. Love, M.D., president and chief executive officer of GBT. “As part o... 
Printer Friendly Version
07/03/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that, on July 2, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 6,500 shares of the Company’s common stock with a per share exercise price of $42.90, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,300 shares of the Company’s common stoc... 
Printer Friendly Version
06/27/18GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease
Primary Endpoint Achieved; 58 Percent of Patients on Voxelotor Dosed with 1500 mg at Week 12 Exceeded 1 g/dL Increase in Hemoglobin Versus 9 Percent of Placebo (p<0.0001) Company Met with FDA on June 25 and Is in Discussions on Potential Accelerated Approval Based on Hemolytic Anemia Efficacy as Assessed by Primary Endpoint Numerically Fewer Vaso-occlusive Crisis (VOC) Episodes in Each Voxelotor Arm Versus Placebo GBT to Host Conference Call and Webcast Today, Wednesday, June 27, at 5:30 ... 
Printer Friendly Version
06/15/18GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress
Data from Four Additional Posters to be Presented, Including New Pharmacokinetic Data from HOPE-KIDS 1 Study Supporting Use of Weight-based Dosing Strategy for Voxelotor Clinical Trials in Children SOUTH SAN FRANCISCO, Calif., June 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new 24-week data from patients treated with the 900 mg dose of voxelotor in the ongoing HOPE-KIDS 1 Study, a Phase 2a open-label study in adolescents ages 6 to 17 years ... 
Printer Friendly Version
06/08/18GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Research’s 12th Annual Symposium
SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts related to the voxelotor program in sickle cell disease will be presented during the Foundation for Sickle Cell Disease Research’s (FSCDR) 12th Annual SCD Research and Educational Symposium in Washington, D.C., taking place June 15-17, 2018. Four encore abstracts have been accepted, including three for oral presentation. Additionally, Kenneth R. ... 
Printer Friendly Version
06/05/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that, on June 1, 2018, the compensation committee of the Company’s board of directors granted three new employees options to purchase an aggregate of 11,500 shares of the Company’s common stock with a per share exercise price of $49.75, the closing trading price on the grant date, and restricted stock units for an aggregate of 7,600 shares of the Company’s common st... 
Printer Friendly Version
05/17/18GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress
SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that data supporting its voxelotor program in sickle cell disease (SCD) will be presented during the 23rd European Hematology Association (EHA) Congress in Stockholm, taking place June 14-17, 2018. A total of five abstracts have been accepted for poster presentation including 24-week data on patients treated with the 900 mg dose of voxelotor in Part B of the HOPE-KID... 
Printer Friendly Version
05/07/18GBT Reports Recent Business Progress and First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2018. "During the first quarter of 2018, we continued to remain focused on the clinical development of voxelotor for the treatment of sickle cell disease, and we have invested further in our commercial infrastructure with the appointment of David L. Johnson as chief commercial offi... 
Printer Friendly Version
05/04/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock.... 
Printer Friendly Version
04/03/18GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco on Tuesday, April 10 at 9:00 a.m. Central European Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover,... 
Printer Friendly Version
04/03/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on April 2, 2018, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 750 shares of the Company’s common stock with a per share exercise price of $44.20, the closing trading price on the grant date, and a restricted stock unit award for 500 shares of the Company’s common stock. All of the above-describe... 
Printer Friendly Version
03/15/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on March 12, 2018, the compensation committee of the Company’s board of directors granted David L. Johnson an option to purchase 55,000 shares of the Company’s common stock with a per share exercise price of $54.05, the closing trading price on the grant date, and a restricted stock unit award for 35,000 shares of the Company’s common stock. All of the above-d... 
Printer Friendly Version
03/12/18Global Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced that the underwriter of its previously announced underwritten public offering has exercised in full its option to purchase an additional 600,000 shares of GBT’s common stock. Inc... 
Printer Friendly Version
03/08/18Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $54.00 per share.  The gross proceeds from this offering are ex... 
Printer Friendly Version
03/08/18Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced a registered offering of 3,500,000 shares of its common stock.  The offering is expected to close on or about March 13, 2018, subject to customary closing conditions.  In additio... 
Printer Friendly Version
03/06/18GBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer
Appointment Strengthens Management Team as Company Advances Clinical Development of Voxelotor, a Potential Disease-Modifying Therapy for Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the “Company”) (Nasdaq:GBT) today announced the appointment of David L. Johnson as chief commercial officer, effective March 12, 2018. Mr. Johnson joins GBT from Gilead Sciences, Inc., where he was vice president, sales and marketing, L... 
Printer Friendly Version
03/05/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ:GBT) today announced that on March 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 7,500 shares of the Company’s common stock with a per share exercise price of $58.80, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,950 shares of the Compa... 
Printer Friendly Version
03/05/18GBT Announces Participation at Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in March 2018: Cowen and Company 38th Annual Health Care Conference in Boston on March 12 at 11:20 a.m. Eastern Time (ET); 28th Annual Oppenheimer Healthcare Conference in New York City on March 20 at 10:55 a.m. ET; and 17th Annual Needham Healthcare Conference in New York City on March 27 at... 
Printer Friendly Version
02/27/18GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the fourth quarter and year ended December 31, 2017. "We continue to build positive momentum toward bringing voxelotor, the first and only sickle cell disease (SCD) treatment to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration, to the SCD community,” said Ted W. Love, M.D., presi... 
Printer Friendly Version
02/07/18GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Wednesday, February 14, 2018 at 9:00 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About Global Blood Therapeutics GBT is a clinical-stage biopharmaceutical compa... 
Printer Friendly Version
01/09/18GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously... 
Printer Friendly Version
01/03/18GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time. The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, deve... 
Printer Friendly Version